Compare ILAG & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ILAG | XBIO |
|---|---|---|
| Founded | 1981 | N/A |
| Country | Hong Kong | United States |
| Employees | N/A | 2 |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 5.8M |
| IPO Year | 2020 | 2011 |
| Metric | ILAG | XBIO |
|---|---|---|
| Price | $2.78 | $2.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 748.0 | ★ 100.9K |
| Earning Date | 04-24-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.52 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,976,411.00 |
| Revenue This Year | N/A | $2.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.04 |
| 52 Week Low | $0.27 | $1.90 |
| 52 Week High | $7.19 | $13.93 |
| Indicator | ILAG | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 35.14 |
| Support Level | $2.60 | $2.14 |
| Resistance Level | $3.32 | $2.62 |
| Average True Range (ATR) | 0.10 | 0.33 |
| MACD | 0.02 | -0.17 |
| Stochastic Oscillator | 33.07 | 6.88 |
Intelligent Living Application Group Inc focuses on designing and producing affordable, high-quality locksets and smart security systems. The company offers high-quality mechanical locksets and smart locks to its customers. Its product portfolio comprises various ODM indoor and outdoor locksets, such as deadbolts, entry locksets, privacy locksets, passage locksets, and storeroom locks, which are marketed through brands like Kambo and Bamberg. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Taiwan.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.